Origin Biosciences, an affiliate of BridgeBio Pharma, is an innovative biotechnology company fully dedicated to NULIBRY, indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

Origin is led by a team of veteran biotechnology executives. Together, with patients and physicians, Origin was able to bring NULIBRY, a safe, effective therapy for MoCD Type A to market. This was done so as quickly as possible because time is of the essence when facing the damage caused by this devastating disorder.